Aralar liver-specific knockout and citrin knockout mouse: a new citrin deficiency model with near-complete hepatic depletion of mitochondrial aspartate-glutamate carriers

Citrin Deficiency (CD) is a metabolic disorder caused by mutations in CITRIN/SLC25A13/AGC2 , which encodes the hepatic mitochondrial aspartate–glutamate carrier (AGC), CITRIN. Loss of CITRIN-mediated aspartate export from mitochondria, either as part of the malate–aspartate shuttle (MAS) or through independent transport activity, underlies key clinical features including hypoglycemia, hyperammonemia, and aversion to carbohydrates and alcohol. Progress in the research of CD mechanisms and therapies has been hindered by lack of adequate models for the condition. For example, the citrin knockout mouse fails to recapitulate the human CD phenotype in vivo, likely due to compensatory expression of the neuronal AGC isoform aralar in murine liver, while the double citrin/glycerophosphate dehydrogenase 2 (gpd2) knockout mouse might present confounding results due to global gpd2 ablation. These limitations underscore the need for a physiologically relevant disease model to support translational research. We generated a double knockout (DLKO) mouse combining global deletion of citrin with liver-specific deletion of aralar using Cre-LoxP technology, resulting in a marked reduction of mitochondrial AGC-MAS activity in hepatocytes. Primary hepatocytes were used to assess cytosolic NADH/NAD⁺ ratios, gluconeogenesis, and urea production. In vivo characterization included biochemical and behavioral analyses, as well as indirect calorimetry to evaluate systemic metabolism. DLKO hepatocytes exhibited elevated cytosolic NADH/NAD⁺ ratios, severely impaired glucose production from lactate, and reduced urea synthesis. These alterations translated in vivo into key features of CD, including hypoglycemia, limited urea cycle capacity, and marked hepatic triglyceride accumulation in the absence of overt liver injury. Behavioral analyses revealed aversion to alcohol and carbohydrates, closely mirroring patient’s food preferences. Importantly, DLKO mice exhibit sex-associated metabolic adaptations: males show growth retardation, hyperphagia, increased energy expenditure, and elevated circulating FGF21 levels, whereas females demonstrate normal food intake and a shift toward lipid metabolism without changes in FGF21. The DLKO mouse represents a robust and physiologically relevant model for the study of Citrin Deficiency. This model overcomes limitations of previous approaches, uncovers distinct systemic metabolic responses in males and females to hepatic MAS dysfunction, and provides a powerful platform for mechanistic studies and preclinical evaluation of therapeutic strategies for CD.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-17
DOI
https://doi.org/10.1186/s12967-026-09222-7
Citations
1
Primary Topic
Metabolism and Genetic Disorders
Type
article
Field-Weighted Citation Impact
3.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aralar liver-specific knockout and citrin knockout mouse: a new citrin deficiency model with near-complete hepatic depletion of mitochondrial aspartate-glutamate carriers

Jorgina Satrústegui, Eduardo Herrada-Soler, Laura Contreras, Ismael García-Lobo et al.
1 citations
Journal of Translational Medicine
Metabolism and Genetic Disorders
3.55
article

Aralar liver-specific knockout and citrin knockout mouse: a new citrin deficiency model with near-complete hepatic depletion of mitochondrial aspartate-glutamate carriers

Jorgina Satrústegui, Eduardo Herrada-Soler, Laura Contreras, Ismael García-Lobo, Beatriz Pardo, Rafael Artuch, Araceli del Arco, Guadalupe Sabio
article en
1 citations

Abstract

Citrin Deficiency (CD) is a metabolic disorder caused by mutations in CITRIN/SLC25A13/AGC2 , which encodes the hepatic mitochondrial aspartate–glutamate carrier (AGC), CITRIN. Loss of CITRIN-mediated aspartate export from mitochondria, either as part of the malate–aspartate shuttle (MAS) or through independent transport activity, underlies key clinical features including hypoglycemia, hyperammonemia, and aversion to carbohydrates and alcohol. Progress in the research of CD mechanisms and therapies has been hindered by lack of adequate models for the condition. For example, the citrin knockout mouse fails to recapitulate the human CD phenotype in vivo, likely due to compensatory expression of the neuronal AGC isoform aralar in murine liver, while the double citrin/glycerophosphate dehydrogenase 2 (gpd2) knockout mouse might present confounding results due to global gpd2 ablation. These limitations underscore the need for a physiologically relevant disease model to support translational research. We generated a double knockout (DLKO) mouse combining global deletion of citrin with liver-specific deletion of aralar using Cre-LoxP technology, resulting in a marked reduction of mitochondrial AGC-MAS activity in hepatocytes. Primary hepatocytes were used to assess cytosolic NADH/NAD⁺ ratios, gluconeogenesis, and urea production. In vivo characterization included biochemical and behavioral analyses, as well as indirect calorimetry to evaluate systemic metabolism. DLKO hepatocytes exhibited elevated cytosolic NADH/NAD⁺ ratios, severely impaired glucose production from lactate, and reduced urea synthesis. These alterations translated in vivo into key features of CD, including hypoglycemia, limited urea cycle capacity, and marked hepatic triglyceride accumulation in the absence of overt liver injury. Behavioral analyses revealed aversion to alcohol and carbohydrates, closely mirroring patient’s food preferences. Importantly, DLKO mice exhibit sex-associated metabolic adaptations: males show growth retardation, hyperphagia, increased energy expenditure, and elevated circulating FGF21 levels, whereas females demonstrate normal food intake and a shift toward lipid metabolism without changes in FGF21. The DLKO mouse represents a robust and physiologically relevant model for the study of Citrin Deficiency. This model overcomes limitations of previous approaches, uncovers distinct systemic metabolic responses in males and females to hepatic MAS dysfunction, and provides a powerful platform for mechanistic studies and preclinical evaluation of therapeutic strategies for CD.

Journal of Translational Medicine
Hospital Sant Joan de Déu Barcelona (ES), Instituto de Salud Carlos III (ES), Spanish National Cancer Research Centre (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Spanish National Centre for Cardiovascular Research (ES), Centro de Biología Molecular Severo Ochoa (ES), Institut de Recerca Sant Joan de Déu (ES), Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ES), Universidad Autónoma de Madrid (ES), University of Castilla-La Mancha (ES)
Centro de Biología Molecular Severo Ochoa, Citrin Foundation, Instituto de Salud Carlos III, Agencia Estatal de Investigación
Good health and well-being
Openalex Percentile: Top 15%
Metabolism and Genetic Disorders
3.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon